拓新药业集团股份有限公司 董事会秘书工作管理制度 第一章 总则 第一条 为进一步明确公司董事会秘书的职责、权限、规范其行为，更好地 发挥其作用，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法》）、《深圳证券交易所创业板股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等有关法律，法规、规范性文件和《拓新药业集团股份有限公司章程》 （以下简称《公司章程》），特制定本工作管理制度。 第二章 董事会秘书的任职资格及聘任与解聘 第二条 董事会设董事会秘书 1 名，董事会秘书为公司与深圳证券交易所的 指定联系人。董事会秘书为公司高级管理人员，对董事会负责。 董事会秘书应当遵守《公司章程》，承担高级管理人员的有关法律责任，对 公司负有诚信和勤勉义务，不得利用职权为自己或他人谋取利益。 第三条 董事会秘书应当具备履行职责所必需的财务、管理、法律专业知识， 具有良好的职业道德和个人品德，并取得证券交易所颁发的董事会秘书资格证书。 董事会秘书应当由上市公司董事、副总裁、财务负责人或者公司章程规定的其他 高级管理人员担任。 第四条 董事 ...

拓新药业集团股份有限公司 董事离职管理制度 第四条 除下列情形外，董事的辞职自公司收到辞职报告之日辞任生效： （一）董事辞职将导致董事会成员低于法定最低人数； （二）独立董事辞职将导致公司董事会或者其专门委员会中独立董事所占比 例不符合法律法规或者《公司章程》的规定，或者独立董事中欠缺会计专业人士。 第一章 总则 第一条 为加强拓新药业集团股份有限公司（以下简称"公司"）对董事 离职管理控制，确保公司治理稳定性，维护公司和股东的权益，根据《中华人民 共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》等法律 法规及《拓新药业集团股份有限公司章程》（以下简称"《公司章程》"）的相 关规定，制定本制度。 第二条 本制度适用于公司董事（含独立董事）因任期届满未连任、辞职、 被解除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条 董事可以在任期届满以前辞任。董事辞任应当向公司提交书面辞 职报告，公司收到辞职报告之日辞任生效，公司将在两个交易日内披露有关情况。 在上述情形下，辞职应当在下任董事填补因其辞职产生的空缺后方能生效。 在辞职生效之前，拟辞职董事仍应当按照有关法律法规和《公司章程》的规定继 ...

拓新药业公告，2025年上半年营业收入1.82亿元，同比下降16.85%。净亏损1828.05万元，上年同期亏 损177.93万元。 ...

[Important Notes, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section covers essential disclaimers, the report's structure, and definitions of key terms for clarity [Important Notes](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The board, supervisory board, and senior management guarantee the report's accuracy, with financial reports affirmed by key personnel, and no dividend distribution planned - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, free from false records, misleading statements, or major omissions, and assume individual and joint legal responsibility[5](index=5&type=chunk) - Company head Yang Xining, chief financial officer Jiao Huijuan, and head of accounting department Yu Zhenwei declare that the financial report in this semi-annual report is true, accurate, and complete[5](index=5&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[6](index=6&type=chunk) [Table of Contents](index=3&type=section&id=%E7%9B%AE%E5%BD%95) This section lists the report's eight main chapters, covering important notes, company profile, management discussion and analysis, corporate governance, significant matters, share changes, bond information, and financial reports, along with their starting page numbers - The report contains eight main chapters, covering comprehensive information on company operations, finance, governance, and significant matters[8](index=8&type=chunk) [Reference Documents](index=4&type=section&id=%E5%A4%87%E6%9F%A5%E6%96%87%E4%BB%B6%E7%9B%AE%E5%BD%95) Reference documents include financial statements signed by the company head and chief accountant, the original semi-annual report signed by the legal representative, and all publicly disclosed company documents and announcements from the reporting period - Reference documents include financial statements signed and sealed by the company head, chief financial officer, and head of accounting department[10](index=10&type=chunk) - Reference documents include the original text of the **2025** semi-annual report signed by the company's legal representative[11](index=11&type=chunk) - Reference documents include the originals of all company documents and announcements publicly disclosed on the CSRC-designated website during the reporting period[12](index=12&type=chunk) [Definitions](index=5&type=section&id=%E9%87%8A%E4%B9%89) This section defines common terms used in the report, including company names, subsidiaries, relevant organizations, industry terms (e.g., API, GMP, DMF), and legal regulations, ensuring accurate understanding of the report content - "Tuoxin Pharmaceutical, the Company, the Shareholding Company" refers to Tuoxin Pharmaceutical Group Co., Ltd. and Xinxiang Tuoxin Pharmaceutical Co., Ltd[15](index=15&type=chunk) - "Active Pharmaceutical Ingredients (API)" refers to the active pharmaceutical ingredients, which are the basic substances constituting the pharmacological action of drugs[15](index=15&type=chunk) - "GMP" refers to Good Manufacturing Practice, which sets clear requirements for raw materials, facilities, equipment, hygiene, personnel training, and quality management required for drug production[15](index=15&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section provides an overview of the company's basic information, contact details, and key financial performance metrics for the reporting period [Company Profile](index=6&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Tuoxin Pharmaceutical Group Co., Ltd., stock abbreviation "Tuoxin Pharmaceutical", stock code **301089**, is listed on the Shenzhen Stock Exchange, with Yang Xining as its legal representative - Company stock abbreviation: **Tuoxin Pharmaceutical**, stock code: **301089**[17](index=17&type=chunk) - Company stock listed on: **Shenzhen Stock Exchange**[17](index=17&type=chunk) - Company legal representative: **Yang Xining**[17](index=17&type=chunk) [Contacts and Contact Information](index=6&type=section&id=%E4%BA%8C%E3%80%81%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) The company's board secretary is Yang Yuhua, and the securities affairs representative is Li Haijing; their contact address is **515 Kelong Avenue, High-tech Zone, Xinxiang City, Henan Province**, with phone/fax **0373-6351918** and email **tuoxinyyh@163.com** - Board Secretary: **Yang Yuhua**; Securities Affairs Representative: **Li Haijing**[18](index=18&type=chunk) - Contact address: **515 Kelong Avenue, High-tech Zone, Xinxiang City, Henan Province**[18](index=18&type=chunk) - Phone/Fax: **0373-6351918**; Email: **tuoxinyyh@163.com**[18](index=18&type=chunk) [Other Information](index=6&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E6%83%85%E5%86%B5) During the reporting period, there were no changes in the company's registered address, office address, website, email, information disclosure and filing locations, or registration status; refer to the **2024** annual report for details - The company's registered address, office address and postal code, website, email, etc., remained unchanged during the reporting period; refer to the **2024** annual report for details[19](index=19&type=chunk) - Information disclosure and filing locations remained unchanged during the reporting period; refer to the **2024** annual report for details[20](index=20&type=chunk) - The company's registration status remained unchanged during the reporting period; refer to the **2024** annual report for details[21](index=21&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In the first half of **2025**, the company's operating revenue decreased by **16.85%** year-on-year, net profit attributable to shareholders plummeted by **927.39%** to **-18.28 million yuan**, operating cash flow turned negative, and total assets and net assets attributable to shareholders both declined 2025 Semi-Annual Key Accounting Data and Financial Indicators | Indicator | Current Period (yuan) | Prior Period (yuan) | Current Period vs. Prior Period Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 181,899,752.24 | 218,756,705.10 | -16.85% | | Net Profit Attributable to Shareholders of Listed Company | -18,280,549.55 | -1,779,323.09 | -927.39% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-Recurring Gains and Losses | -22,207,618.53 | -7,967,008.09 | -178.74% | | Net Cash Flow from Operating Activities | -23,014,635.10 | 59,959,775.55 | -138.38% | | Basic Earnings Per Share (yuan/share) | -0.14 | -0.01 | -1,300.00% | | Diluted Earnings Per Share (yuan/share) | -0.14 | -0.01 | -1,300.00% | | Weighted Average Return on Net Assets | -1.18% | -0.11% | -1.07% | | **Period-End** | **Prior Year-End** | **Period-End vs. Prior Year-End Change** | | Total Assets | 1,707,229,980.16 | 1,758,243,932.05 | -2.90% | | Net Assets Attributable to Shareholders of Listed Company | 1,534,239,510.89 | 1,552,520,060.44 | -1.18% | [Differences in Accounting Data under Domestic and Overseas Accounting Standards](index=7&type=section&id=%E4%BA%94%E3%80%81%E5%A2%83%E5%86%85%E5%A

资料显示，拓新药业集团股份有限公司位于河南省新乡市高新区科隆大道515号，成立日期2005年2月3 日，上市日期2021年10月27日，公司主营业务涉及化学合成、生物发酵核苷(酸)类原料药及医药中间体 的研发、生产及销售。主营业务收入构成为：核苷酸系列38.10%，嘌呤系列31.74%，嘧啶系列 19.06%，其他7.97%，核苷系列3.13%。 截至7月31日，拓新药业股东户数2.25万，较上期增加7.72%；人均流通股4048股，较上期减少7.16%。 2025年1月-3月，拓新药业实现营业收入9699.47万元，同比减少10.46%；归母净利润-356.47万元，同比 减少272.34%。 分红方面，拓新药业A股上市后累计派现9463.61万元。近三年，累计派现8203.61万元。 责任编辑：小浪快报 8月25日，拓新药业涨1.67%，成交额2.53亿元。两融数据显示，当日拓新药业获融资买入额2803.39万 元，融资偿还2420.21万元，融资净买入383.18万元。截至8月25日，拓新药业融资融券余额合计1.81亿 元。 融资方面，拓新药业当日融资买入2803.39万元。当前融资余额1.81亿元，占 ...

证券日报网讯8月22日晚间，拓新药业（301089）发布公告称，公司监事会于近日收到公司职工代表监 事黄国栋先生的书面辞职报告。黄国栋先生因个人原因申请辞去公司第五届监事会职工代表监事职务。 黄国栋先生原定任期至第五届监事会届满日(2027年5月12日)，辞职后黄国栋先生不在公司担任其他职 务。 ...

（记者 王瀚黎） 每经头条（nbdtoutiao）——核心产品净值仅剩7毛钱，昔日"公募一哥"任泽松怎么了？牛市踏空真相曝 光 每经AI快讯，拓新药业8月22日晚间发布公告称，黄国栋先生因个人原因申请辞去公司第五届监事会职 工代表监事职务。 ...

拓新药业集团股份有限公司 关于职工代表监事辞职的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在任何虚假记载、误导性陈 述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）监事会于近日收到公司职 工代表监事黄国栋先生的书面辞职报告。黄国栋先生因个人原因申请辞去公司第 五届监事会职工代表监事职务。黄国栋先生原定任期至第五届监事会届满日 （2027 年 5 月 12 日），辞职后黄国栋先生不在公司担任其他职务。 证券代码：301089 证券简称：拓新药业 公告编号：2025-036 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》和《公司章程》等有关规定，黄国栋先生辞职之后，公司监 事会职工代表的比例低于监事会成员的三分之一，其辞职申请将在公司补选产生 新任监事后生效。在此之前，黄国栋先生将继续履行监事职责。黄国栋先生的辞 职不会影响公司及监事会的正常运作，公司将按照相关规定尽快完成监事的补选 工作或依法取消监事会设置。 截至本公告披露日，黄国栋先生未持有公司股份，也不存在应当履行而未履 行的承诺事项。黄国栋先生在任职期间恪尽职守，勤勉尽责，公司 ...

Group 1 - The article highlights the success of Tuoxin Pharmaceutical Group under the leadership of Chairman Yang Xining, emphasizing the company's journey from a technology-driven startup to a leading player in the pharmaceutical industry, culminating in its successful listing on the capital market [2] - Yang Xining's focus on core technologies, particularly in the field of nucleoside (acid) raw materials and pharmaceutical intermediates, has established Tuoxin Pharmaceutical as a leader in this high-barrier segment, with a comprehensive product chain covering various therapeutic areas [3] - The company has implemented international quality standards, achieving ISO9001 certification and GMP management for raw material production, which has facilitated its global market entry and product registration in countries like India and Uzbekistan [5] Group 2 - Under Yang Xining's leadership, Tuoxin Pharmaceutical has received multiple awards for its scientific contributions, including the "National Science and Technology Progress Award" and recognition as a "National High-tech Industry Demonstration Project," showcasing its research and industrial transformation capabilities [6] - Yang Xining actively engages in social responsibility and industry development, contributing to regional economic growth and fostering talent through academic collaborations and mentorship roles [8] - The successful listing of Tuoxin Pharmaceutical on the Shenzhen Stock Exchange in October 2021 marks a significant milestone, reflecting the company's robust development and setting the stage for future growth through capital market leverage [8]

证券日报网讯拓新药业（301089）8月15日在互动平台回答投资者提问时表示，公司及子公司专注于核 苷(酸)类原料药及医药中间体的研发、生产及销售，主要产品包括胞磷胆碱钠、利巴韦林、盐酸阿糖胞 苷、胞嘧啶等，应用于抗病毒、抗肿瘤和神经系统用药领域。未来公司将持续深耕核心领域，加大抗肿 瘤、抗病毒领域核苷(酸)类产品的研发工作，并积极拓展大健康赛道，同时力争实现从中间体到原料 药、制剂的全产业链突破。 ...